نتایج جستجو برای: ctdna
تعداد نتایج: 831 فیلتر نتایج به سال:
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal growth factor receptor (EGFR). The assays largely depend on the acquisition of tumor tissue via biopsy before the initiation of therapy or after the onset of acquired resistance. However, the limitations of tissue biopsy including tumor heterogeneity and insufficien...
INTRODUCTION The potential of oncogene-driven targeted therapy is perhaps most fully realized in non-small cell lung cancer (NSCLC), given the number of genomic targets and approved matched therapies. However, invasive tissue biopsy at the time of each disease progression may not be possible and is associated with high morbidity and cost. Use of newly available "liquid biopsies" can circumvent ...
Recent advances in next-generation sequencing (NGS) have enabled the quantitation of circulating tumour DNA (ctDNA) encoding the clonal rearranged V(D)J immunoglobulin locus. We aimed to evaluate the clonal heterogeneity of follicular lymphoma (FL) in the tumour and the plasma at diagnosis and to assess the prognostic value of the ctDNA level. Plasma samples at diagnosis were available for 34 p...
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg ...
Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor's dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is not always feasible or practical and may underestimate intratumoral heterogeneity. Technological...
Circulating tumor DNA (ctDNA) is released by cancer cells into body fluids. The collection of fluids that contains ctDNA, also known as lliquid biopsy, allows to access through a minimally invasive procedure. ctDNA has been proposed alternative source for genotyping purposes and longitudinal genetic monitoring. Also, radiation-free tool the early identification chemorefractory patients. We will...
decision-making on an individual basis. amenable to personalized genomics, where the level and type of mutations in ctDNA would inform clinical plasma of patients with less advanced cancers. Nevertheless, once optimized, this ''liquid biopsy'' approach will be TAm-Seq will need to achieve a more sensitive detection limit (<2% allele frequency) to identify mutations in the large regions of ctDNA...
Tissue biopsy has long served as the mainstay of cancer diagnosis, staging, and therapeutic decisions, with its role evolving from simple histologic examination to complex genetic analysis. Despite its utility, biopsy represents only a single time point from a single location, often proving inadequate at fully characterizing a malignancy and its evolution because nearby tissue might contain add...
Deep sequencing is required for the highly sensitive detection of rare variants in circulating tumor DNA (ctDNA). However, there remains a challenge for improved sensitivity and specificity. Maximum-depth sequencing is crucial to detect minority mutations that contribute to cancer progression. The associated costs become prohibitive as the numbers of targets and samples increase. We describe th...
1. Abstract 2. Introduction 3. Experimental procedures 3.1. Reagents 3.2. Apparatus 3.3. Electrode preparation 4. Results and discussion 4.1. Preparation and characteristics of nano-SnO2 4.1.1. The preparation of nanoSnO2 4.1.2. The characteristics of nano-SnO2 4.2. Electrochemical behaviors of CFX at the nano-SnO2 modified electrode 4.2.1. Cyclic voltammograms of CFX at various modified electr...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید